Tag: <span>vaccines</span>

Despite the existence of effective vaccines against Hepatitis B virus, the infection with it remains an important problem worldwide due to its association with hepatocellular carcinoma. Several procedures have been used to purify the Hepatitis B surface antigen (HBsAg) for immunization purposes. Immuno-purification using HBsAg-specific murine monoclonal antibodies (MAbs) has been one of the most successful strategies for such a purpose due to the high antigen selectivity (high affinity) of MAbs…

Biologics Production

The Vero cell line is one of the most widely used continuous cell lines in the world, cited in over 10,000 publications. Though originally developed as a host for viral replication, uses for this highly adaptable cell line have expanded far beyond the research laboratory to include diagnostic practices in hospitals, epidemiological surveys, in vitro fertilization clinics, bacterial toxin assays, and vaccine production. ATCC has played a pivotal role in this expansion by distributing the Vero cell line, ATCC® CCL-81™, to the worldwide scientific research community. Recently, ATCC developed a fully-characterized master cell bank of Vero cells prepared under current good manufacturing practice (cGMP) conditions (ATCC® CCL-81.4™). This report traces the history of the Vero cell line from its origins in the laboratory of Dr. Yosihiro Yasumura to its use as a continuous cell substrate for vaccine manufacturing…

Biologics Production Cell & Tissue Banking

The biologics market, although difficult to estimate, is currently thought to be in excess of $20 billion. In recent years, the growth in the novel therapeutics market has continued to exceed all but the most optimistic of expectations. The number of products in early stage trials may already be over 1,000, with an estimated 40 or so additional products in the process of finally being released to the market. The biologics market is led by relatively few “blockbuster” drugs, but the breadth of novel products continues to expand. This has resulted in exciting times for clinicians but has resulted in concern related to the bottleneck of production capacities for these drugs, as well as the pressure from healthcare agencies to reduce the cost of goods…

Baculovirus Expression Technology Biologics Production

Vaccines represent the most effective means of disease prevention. A variety of vaccines including live-attenuated strains, inactivated organisms, and subunit forms are currently in use. However, advances in molecular biology, virology and immunology have made new classes of potential vaccines possible. One such class currently being developed by AlphaVax is based on an alphavirus-derived expression system. Alphaviruses are members of the Togaviridae family and have positive-sense RNA genomes. The RNA genome is surrounded by a capsid composed of 240 copies of a single capsid protein. Alphaviruses are enveloped viruses that mature at the plasma membrane of the host cell and are 50-70 nm in diameter. The viral envelope contains 80 trimers composed of two viral glycoproteins, E1 and E2. These trimers contain three E1-E2 heterodimers and are arranged in the viral envelope as spikes which protrude from the surface of the virus particle…

Biologics Production Manufacturing Viral Vectors

Adenoviral vectors (AAV’s) offer a promising new approach to vaccine development. They have the ability to be rapidly manipulated for bearing transgenic coding for specific antigenic proteins, efficiently infect a variety of mammalian cell types (including antigen-presenting cells) and induce a broad immune response against the target antigen in vaccine recipients. Furthermore, AAV’s offer an excellent safety profile, in that they can be engineered to be non-replicating in the vaccine recipient and they lack the molecular mechanism for integration into the host genome. AAV’s are highly amenable to scalable manufacturing processes such as the use of stirred tank bioreactors, high capacity filtration methods, and chromatographic purification procedures…

Biologics Production Viral Vectors

Despite 20 years of intensive research, the development of an effective vaccine to combat the worldwide AIDS pandemic remains an elusive goal. Currently, more than 40 million individuals are infected with human immunodeficiency virus (HIV) and there have been more than 25 million related deaths. Globally, the rate of new infections is alarming, with ten new infections occurring every minute. Ninety-five percent of these infections occur in the developing world. Several significant challenges face the development of an effective HIV vaccine…

Manufacturing Viral Vectors

Chronic viral infections are major healthcare issues. Hepatitis B virus (HBV), hepatitis C virus (HCV), human papilloma virus (HPV), and human immunodeficiency virus (HIV) are prime examples of viruses which cause chronic infections. HBV is a member of a family of DNA viruses that primarily infect liver cells which can lead to acute or chronic liver disease. Approximately 3–5% of adults and 90% of infants infected by HBV become chronic carriers of the virus. More than 350 million people worldwide are chronically infected by HBV. Chronic HBV carriers have a significant probability of developing cirrhosis of the liver and hepatocellular carcinoma. There are effective prophylactic vaccines for HBV infection, but these have proven ineffective against chronic infections. Antiviral agents are effective in controlling the viremia, but the emergence of mutant strains of the virus is a cause for concern…

Baculovirus Expression Technology

As human immunodeficiency virus type-1 (HIV-1) continues to spread around the world, scientists are actively pursuing effective vaccines against the infectious disease that results in AIDS. A number of vaccine designs have been developed, including plasmid DNA constructs encoding HIV proteins. One advantage of DNA vaccination is that after the uptake of the plasmid by the host cells, the encoded antigens are expressed in the native conformation and allow authentic immunological processing of the antigen. Another advantage of DNA vaccines is that they can be repeatedly administered without vector-directed immunity limiting the efficacy of the boost. DNA vaccines alone can induce both humoral and cellular immune responses and provide modest protection against disease progression in the preclinical, nonhuman primate model when challenged with simian immunodeficiency virus (SIV)…

Biologics Production

The United States Pharmacopeia (USP) is a not-for-profit nongovernmental organization founded in 1820 that develops public standards for drug substances and products; these standards are enforceable by FDA and have been adopted by many nations around the world. USP General Chapters provide industrial and academic researchers alike with crucial guidance, particularly in areas where there is a regulatory void. A good recent example is the proposed USP general information chapter…

Regulatory

The Dale and Betty Bumpers Vaccine Research Center (VRC) at the National Institutes of Health (NIH) was established to facilitate research in vaccine development. The VRC is dedicated to improving global human health through the rigorous pursuit of effective vaccines for human diseases. It was established by former president Bill Clinton as part of an initiative to help develop an AIDS vaccine and is part of the NIAID organization. Since the inception of the VRC, its mission has expanded to include the development of vaccines against bioterrorism and emerging infectious diseases…

Research